Drugs / Anti-PD-1 antibody
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04004234 | Mar 2019 → Aug 2020 | biliary tract cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05771402 | Oct 2023 → Dec 2026 expected | autoimmune pulmonary disease due to PD-1 deficiency, chronic hepatitis B virus infection, interferon antiviral depressor | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-PD-1 antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04004234 ↗ |
| Action | Inhibit | “Anti-PD-1 monoclonal antibody; PD-1 inhibitor” NCT04004234 ↗ |
| Modality | Monoclonal antibody | “Anti-PD-1 monoclonal antibody; PD-1 inhibitor” NCT04004234 ↗ |
| Route | Intravenous | “Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle” NCT04004234 ↗ |